
If carbs never seem to fill you up, there's a reason. In a small 1996 study, lean women released a strong GLP-1 response after a carb meal, while women with obesity barely responded.
After a fat meal, both groups responded about the same. GLP-1 is your gut's fullness hormone, and with insulin resistance the carb signal gets much weaker.
In this episode, I walk through how to work with the signal your body still has:
- Why a low-carb or ketogenic diet fits: fat and protein still trigger GLP-1, and ketones turn down ghrelin, your hunger hormone
- Natural GLP-1 boosters: protein first, yerba mate, allulose and a healthy gut microbiome, plus how strong the evidence is for each
- What new research says about GLP-1 drugs
- Why I see the drugs as a temporary bridge for carb cravings: lowest dose, with an exit plan, strength training and real food habits
This episode is for education only and isn't medical advice. Talk to your doctor before starting or changing any medication.
CONNECT WITH ME
Website: http://metabolicdaria.com
YouTube: https://www.youtube.com/@Metabolic-Daria
Instagram: https://www.instagram.com/metabolicdaria/
SOURCES
Ranganath et al. 1996, GLP-1 in obesity (Gut): https://pmc.ncbi.nlm.nih.gov/articles/PMC1383202
GLP-1 defect after lowering fatty acids (Surrey thesis): https://openresearch.surrey.ac.uk/esploro/outputs/doctoral/The-Role-of-Glucagon-Like-Peptide-1-and/99516004402346
GLP-1 before and after weight loss (IJO): https://www.nature.com/articles/0801655.pdf
Ketone drink lowers ghrelin and appetite (2018): https://www.dpag.ox.ac.uk/publications/publication_modal/743590
Ketosis lowers ghrelin, not GLP-1: https://research.regionh.dk/da/publications/acute-ketosis-inhibits-appetite-and-decreases-plasma-concentratio/
Yerba mate and GLP-1 (Nutrients 2025): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11858593/
Allulose and GLP-1 (J Nutr 2022): https://pmc.ncbi.nlm.nih.gov/articles/PMC9071322
Allulose trial protocol (2026): https://www.researchprotocols.org/2026/1/e81857
Whey protein pre-load trial (Diabetologia 2014): https://pubmed.ncbi.nlm.nih.gov/25005331/
Short-chain fatty acids and GLP-1 (Diabetes 2012): https://pubmed.ncbi.nlm.nih.gov/22190648/
Akkermansia human evidence: https://acibademinternational.com/blog/akkermansia-the-next-generation-probiotic-what-human-data-show/
Weight regain after stopping (BMJ 2025): https://bmjgroup.com/stopping-weight-loss-drugs-linked-to-weight-regain-and-reversal-of-heart-health-markers/
Weight regain review (Cambridge 2026): https://www.uspharmacist.com/article/weight-regain-common-after-stopping-glp1-drugs
Muscle vs. liver on GLP-1s (Cell Reports Medicine 2026): https://bioseb.com/en/module/prestablog/news?id=2394
2026 body composition review: https://substance-over-noise.beehiiv.com/p/how-much-muscle-are-glp-1-patients-actually-losing
Regulators on GLP-1s and mental health: https://ro.co/perspectives/glp1s-mental-health/
GLP-1s and suicidality review (2026): https://orb.binghamton.edu/pharmacy_fac/112
Semaglutide and alcohol cravings (JAMA Psychiatry 2025): https://www.emjreviews.com/neurology/news/semaglutide-cuts-alcohol-cravings-in-new-trial/
Low-dose GLP-1 outcomes: https://www.epocrates.com/online/article/is-glp-1-microdosing-effective
Low-dose semaglutide preprint (2026): https://www.preprints.org/manuscript/202606.0636
FDA winds down GLP-1 compounding: https://www.techtarget.com/pharmalifesciences/news/366621720/FDA-winds-down-GLP-1-compounding-policies
Compounded GLP-1 timeline: https://www.americanmedspa.org/news/compounded-glp-1-faq/
Weitere Episoden von „Metabolic Daria“



Verpasse keine Episode von “Metabolic Daria” und abonniere ihn in der kostenlosen GetPodcast App.






